All Episodes

October 27, 2025 β€’ 4 mins

πŸ’ŠπŸ«€ Aspirin in the Crosshairs?

The AQUATIC Trial (NEJM, Aug 2025) raises sharp questions on dual-pathway therapy in chronic coronary syndrome (CCS) patients already on long-term anticoagulation.

πŸ“‰ Adding aspirin led to:

β€’ ↑ Ischemic events (HR 1.53; P=0.02)

β€’ ↑ Mortality (HR 1.72; P=0.01)

β€’ ↑ Major bleeding (HR 3.35; P<0.001)

🧠 Takeaway: More isn't always better. In high-risk CCS, aspirin may harm more than help.

πŸ“š Read: https://www.nejm.org/doi/full/10.1056/NEJMoa2507532

#Cardiology #Antiplatelet #NEJM #PrecisionMedicine #AQUATICTrial

Mark as Played

Advertise With Us

Popular Podcasts

Stuff You Should Know
Dateline NBC

Dateline NBC

Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

On Purpose with Jay Shetty

On Purpose with Jay Shetty

I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted β€” click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!

Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

Β© 2025 iHeartMedia, Inc.